BIOMAT Database Logo BIOMAT Database Logo

Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. 1995

L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.

MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes (TIL) from melanoma patients. In the present study we have analyzed 10 potential 9-mer epitopes containing the HLA-A2.1 binding motifs for their ability to induce melanoma-specific T cell lines. Antimelanoma CTL could be generated only with MART-1(27-35) peptide, which has been previously shown to be recognized by a majority of HLA-A2-restricted TIL. Anti-MART-1(35-43)-specific CTL could also be induced, but these T cells did not recognize melanoma cells. MART-1(27-35)-specific CTL could be effectively generated from a total of 11 of 12 PBL and from 3 of 3 TIL derived from HLA-A2+ melanoma patients, as well as from 2 of 4 PBL from HLA-A2+ healthy donors by in vitro stimulation with autologous PBMC pulsed with the synthetic MART-1(27-35) peptide. These CTL lines specifically lysed and release cytokines (TNF-alpha, IFN-gamma, and GM-CSF) in response to T2 cells pulsed with MART-1(27-35), as well as to HLA-A2+ MART-1+ melanoma cells. CTL generated with MART-1(27-35) also lysed uncultured HLA-A2+ melanoma cells derived from tumor biopsies, indicating that this MART-1 epitope is likely to be expressed in association with HLA-A2 on the surface of tumor cells in vivo. CTL lines generated with MART-1(27-35) mediated 25- to 100-fold higher lytic activity than MART-1-reactive CTL grown from TIL in the presence of high dose IL-2. These results demonstrate that MART-1(27-35) peptide may represent an ideal candidate for Ag-specific immunotherapy in melanoma patients.

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009842 Oligopeptides Peptides composed of between two and twelve amino acids. Oligopeptide
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein

Related Publications

L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues.
February 1998, Journal of immunology (Baltimore, Md. : 1950),
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
December 1997, Cancer research,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Induction of tumor-infiltrating lymphocytes in human malignant melanoma metastases by immunization to melanoma antigen vaccine.
August 1989, Journal of biological response modifiers,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide.
August 1994, Cancer immunology, immunotherapy : CII,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Cross-presentation of human melanoma peptide antigen MART-1 to CTLs from in vitro reconstituted gp96/MART-1 complexes.
April 2004, Cancer immunity,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
January 1995, Journal of immunology (Baltimore, Md. : 1950),
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
High avidity melanoma-reactive cytotoxic T lymphocytes are efficiently induced from peripheral blood lymphocytes on stimulation by peptide-pulsed melanoma cells.
April 2000, Clinical cancer research : an official journal of the American Association for Cancer Research,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.
January 1997, Cytotechnology,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1(27-35).
August 1996, The Journal of experimental medicine,
L Rivoltini, and Y Kawakami, and K Sakaguchi, and S Southwood, and A Sette, and P F Robbins, and F M Marincola, and M L Salgaller, and J R Yannelli, and E Appella
Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
July 2002, Chinese medical journal,
Copied contents to your clipboard!